Ver mas grande
ELISA Kit for Phospholipase A2 Group VII (LpPLA2)
CC-SEA867Hu
Producto nuevo
48T, 96T, 96T×5, 96T×10, 96T×100
Comprando este producto generará 6 Biopuntos. Su cesta contiene un total 6 Biopuntos puede ser convertido en un Biobonos Descuento 24.00EUR.
Hoja técnica
| Size | 96T |
| Storage Conditions | -20°C |
| Shipping Conditions | Entre 4°C y 8°C |
| Applications | Enzyme-linked immunosorbent assay for Antigen Detection. |
| Detection Range | 0.625-40ng/mL |
| Sensitivity | The minimum detectable dose of this kit is typically less than 0.255ng/mL |
| Research Area | Enzyme & Kinase |
| Organism species | Homo sapiens (Human) |
| Alternative Names | PLA2G7 |
| Item Name | Phospholipase A2 Group VII |
| Assay Length | 3h |
| Method | Double-antibody Sandwich |
| Sample Type | Serum, plasma and other biological fluids |
| Formato | 48T, <i>96T</i>, 96T×5, 96T×10, 96T×100 |
| Test Principle | The test principle applied in this kit is Sandwich enzyme immunoassay. The microtiter plate provided in this kit has been pre-coated with an antibody specific to Phospholipase A2 Group VII (LpPLA2). Standards or samples are then added to the appropriate m |
| Assay procedure summary | 1. Prepare all reagents, samples and standards |
| UniProt ID | Q13093 |
Más información
CITATIONS
The effects of different intensity walking programs on serum blood lipids, high-sensitive C-reactive protein, and lipoprotein-associated phospholipase A2 in premenopausal women;Association of Serum Lipoprotein-Associated Phospholipase A2 Level with Nonalcoholic Fatty Liver Disease;Effects of Pycnogenol on endothelial function in patients with stable coronary artery disease: a double-blind, randomized, placebo-controlled, cross-over study;Effects of Lipid-Lowering Drugs on Irisin in Human Subjects In Vivo and in Human Skeletal Muscle Cells Ex Vivo;Everolimus therapy is associated with reduced lipoprotein-associated phospholipase A2 (Lp-Pla2) activity and oxidative stress in heart transplant recipients.;Lipoprotein-Associated Phospholipase A2 Mass Level Is Increased in Elderly Subjects with Type 2 Diabetes Mellitus;The Role of Asymmetric Dimethylarginine and Lipoprotein Associated Phospholipase A2 in Children and Adolescents with Dyslipidemia;In vitro lipid-lowering and fibrinolytic effects of regulatory leucine-containing glyprolines in human blood;Lipoprotein-associated phospholipase A2 and AGEs are associated with cardiovascular risk factors in women with history of gestational diabetes mellitus.;Lipoprotein-Associated Phospholipase A 2 Mass Level Is Increased in Elderly Subjects with Type 2 Diabetes Mellitus;Effects of sitagliptin therapy on markers of low-grade inflammation and cell adhesion molecules in patients with type 2 diabetes;Effect of Extended‐Release Niacin on High‐Density Lipoprotein (HDL) Functionality, Lipoprotein Metabolism, and Mediators of Vascular Inflammation in Statin‐Treated Patients;V;Effect of Pitavastatin Treatment on ApoB-48 and Lp-PLA2 in Patients with Metabolic Syndrome: Substudy of PROspective Comparative Clinical Study Evaluating the Efficacy and Safety of PITavastatin in Patients with Metabolic Syndrome;Effect of dipyridamole on myocardial reperfusion injury: A double‐blind randomized controlled trial in patients undergoing elective coronary artery bypass surgery;Effect of intensive insulin treatment on plasma levels of lipoprotein-associated phospholipase A 2 and secretory phospholipase A 2 in patients with newly …;SERUM LIPOPROTEIN-ASSOCIATED PHOSPHOLIPASE A2 IN MALES WITH METABOLIC SYNDROME AND OBSTRUCTIVE SLEEP APNEA.;Biomarker for diagnosis of moyamoya disease;Circulating fatty-acid binding-protein 4 levels predict CV events in patients after coronary interventions;Can admission lipoprotein-associated phospholipase A2 predict the symptomatic cerebral vasospasm following aneurysmal subarachnoid hemorrhage?;